Sugi Predict

Sugi Predict / Targets / NR4A1

NR4A1

Nuclear receptor subfamily 4immunitygroup A member 1 · P22736 · NR4A1 on Sugi Atlas →

71,206 patent compounds predicted against NR4A1, 53,863 high-confidence (nearest known ligand ≥ 0.5)

Top predicted compounds (top 20 by supporting neighbours, then confidence)

CompoundConfidenceSupporting neighbours
Pristimerin Pristimerin (SCHEMBL15020) 1.00 10/20
Celastrol Celastrol (SCHEMBL14954) 0.84 7/20
SCHEMBL19918 SCHEMBL19918 0.83 7/20
SCHEMBL19727 SCHEMBL19727 0.80 7/20
SCHEMBL19721 SCHEMBL19721 0.77 7/20
SCHEMBL19759 SCHEMBL19759 0.73 7/20
SCHEMBL20869 SCHEMBL20869 0.73 7/20
SCHEMBL19570 SCHEMBL19570 0.73 7/20
SCHEMBL20780 SCHEMBL20780 0.71 7/20
SCHEMBL20022 SCHEMBL20022 0.70 7/20
SCHEMBL20433 SCHEMBL20433 0.69 7/20
SCHEMBL20028 SCHEMBL20028 0.68 7/20
SCHEMBL20479 SCHEMBL20479 0.66 7/20
SCHEMBL21536 SCHEMBL21536 0.66 7/20
SCHEMBL20252 SCHEMBL20252 0.65 7/20
Tingenone Tingenone (SCHEMBL17064) 0.65 7/20
SCHEMBL20173 SCHEMBL20173 0.64 7/20
SCHEMBL20107 SCHEMBL20107 0.64 7/20
SCHEMBL20611 SCHEMBL20611 0.54 6/20
SCHEMBL20399 SCHEMBL20399 0.50 6/20

Clinical trials — most relevant to NR4A1 by text similarity (a relevance ranking, not an exhaustive list)

TrialPhaseStatus
Chronic Effects of Estrogen in Microcirculation PHASE4COMPLETED
Investigating the Potential Role of Aerosolized Retinoic Acid, a Potent Vitamin A Metabolite for Treating COVID-19 Anosmia and Retinoic Acid Insufficiency .A Novel Approach for Regaining Sense of Smell. PHASE4UNKNOWN
Fulvestrant in Metastatic Breast Cancer PHASE4UNKNOWN
The Use of Inhaled Corticosteroids in the Treatment of Asthma is Children in the Emergency Room PHASE2/PHASE3COMPLETED
Effects of Pioglitazone on High-density Lipoprotein (HDL) Function in Persons With Diabetes PHASE3COMPLETED
Oral NRX 194204 Study in Patients With Advanced Non-Small Cell Lung Cancer (NSCLC) PHASE2UNKNOWN
Fibrates in Pediatric Cholestasis PHASE2COMPLETED
N-DOSE: A Dose Optimization Trial of Nicotinamide Riboside in Parkinson's Disease PHASE2COMPLETED
A Window of Opportunity Study of Pre-operative Endocrine Therapy With and Without Prometrium in Postmenopausal Women With Early Stage Breast Hormone Receptor Positive (HR+) Human Epidermal Receptor 2 Negative (HER2-) Breast Cancer. PHASE2UNKNOWN
Activity of Regorafenib in Combination With Chemotherapy in Patients With Advanced Biliary Tract Cancer PHASE1/PHASE2COMPLETED
A Study of Bezafibrate in Mitochondrial Myopathy PHASE2COMPLETED
Preoperative Bexarotene Treatment for Cushing's Disease PHASE1/PHASE2UNKNOWN
Study Evaluating Toxicity & Efficacy of Lenalidomide(Revlimid®)in Chemotherapy-Naïve AIPC Patients PHASE2COMPLETED
Neoadjuvant Zoledronate and Atorvastatin in Triple Negative Breast Cancer PHASE2COMPLETED
Meclizine for Hepatocellular Carcinoma PHASE1COMPLETED
Personalised Pharmacological Approach to the Tapering of Corticosteroid Doses in Systemic Lupus Patients Treated With Prednisone nanCOMPLETED
The Impact of Pharmacological and Electric Modulation of NMDA Pathway on the Cognitive Flexibility and Volitional Movement Preparation in Patients With Parkinson's Disease nanCOMPLETED
The Role of Programmed Death Ligand -1 (Pdl-1) in Lung Cancer nanCOMPLETED
Prognostic Value of Vitamin D Levels in Egyptian Females With Breast Cancer nanUNKNOWN
RORC Genetic Polymorphism of Rheumatoid Arthritis nanCOMPLETED
Clinical and Basic Research on the Necessity of Scar Tissue Resection During Intrauterine Adhesions nanUNKNOWN
The Impact of Selective Vitamin D Receptor Activation on Clinical Outcomes in Septic Patients nanNOT_YET_RECRUITING
Steroid Treatment of Idiopathic Nephrotic Syndrome nanCOMPLETED
Study of Tissue Samples From Women Treated With Paclitaxel for Breast Cancer on Clinical Trial CALGB-9344 or CALGB-9741 nanCOMPLETED
Precision High-Intensity Training Through Epigenetics (PHITE) nanCOMPLETED
Comparison of Salivary Biormarkers Levels With Periodontal Clinical Parameters in Smokers and Non-Smokers With Different Periodontal Diseases nanCOMPLETED
Immunolocalization of 1,25,Dihydroxyvitamin D3 in Aggressive Periodontitis Patients nanCOMPLETED
Study IL- 35 Level and Fibronectin Type Ⅲ Domain Containing Protein 5 \ Irsin (FNDC5 rs3480) Gene Variations in Chronic Hepatitis B. nanUNKNOWN
Potential Role of Inflammasome NLRP3 And IL-1B Gene Expression in COVID-19 Patients: Impact of Ferretin and D -Dimer. nanUNKNOWN
Effects of Losartan on Insulin Sensitivity and Secretion in Type 2 Diabetes and Nephropathy nanCOMPLETED

Related proteins — ESM-2 sequence neighbours (a NR4A1 binder may also engage these)

ProteinNameSimilarity
P51666 — 1.000 P51666 →
P12813 — 1.000 P12813 →
Q0V8F0 — 1.000 Q0V8F0 →
P22829 — 1.000 P22829 →
Q9QZB6 — 1.000 Q9QZB6 →
P16058 — 0.997 P16058 →
Q9YH33 — 0.996 Q9YH33 →
POU5F1 POU domain, class 5, transcription factor 1 0.995 landscape →
Q6QMY5 — 0.994 Q6QMY5 →
NR4A3 Nuclear receptor subfamily 4 group A member 3 0.993 landscape →
A1YER0 — 0.993 A1YER0 →
O97952 — 0.993 O97952 →
Q00175 — 0.993 Q00175 →
Q9H329 — 0.993 Q9H329 →
P49699 — 0.993 P49699 →
O97776 — 0.993 O97776 →
Q3UJB9 — 0.992 Q3UJB9 →
Q9JHS1 — 0.992 Q9JHS1 →
D3ZJK7 — 0.992 D3ZJK7 →
Q95171 — 0.992 Q95171 →
P50569 — 0.991 P50569 →
RXRB Retinoic acid receptor RXR-beta 0.991 landscape →
A2AEV7 — 0.991 A2AEV7 →
P51179 — 0.991 P51179 →
RORC Nuclear receptor ROR-gamma 0.991 landscape →
P33242 — 0.991 P33242 →
Q6DN90 — 0.991 Q6DN90 →
A7X8B5 — 0.991 A7X8B5 →
P57100 — 0.991 P57100 →
Q5RAP4 — 0.991 Q5RAP4 →